pyrogastrone and Esophagitis--Peptic

Eighty patients with reflux oesophagitis were randomised to receive either Pyrogastrone five tablets daily or cimetidine 400 mg twice daily for six weeks, extended to 12 if necessary. At six weeks, 49% of the Pyrogastrone treated subjects and 37% of the cimetidine treated subjects were healed. After 12 weeks the cumulative healing rates were 64% for Pyrogastrone and 66% for cimetidine. Compared with baseline both drugs achieved similarly significant improvements in symptom score, endoscopic and histological grading even in those who did not heal completely. Response was not related to length of symptoms or initial severity of oesophagitis. Eleven of 25 (44%) patients healed with Pyrogastrone relapsed within one year compared with 15 of 27 (56%) healed with cimetidine. Although this trend in favour of Pyrogastrone was not significant at one year the early relapse rate was significantly greater in cimetidine treated subjects. At six weeks, five cimetidine treated subjects had relapsed compared with none in the Pyrogastrone group (p = 0.05). This study shows that Pyrogastrone and cimetidine are equally effective in the healing of oesophagitis and raises the possibility that Pyrogastrone has marginal benefits in terms of time to relapse.

Topics: Alginates; Aluminum Hydroxide; Antacids; Bicarbonates; Carbenoxolone; Cimetidine; Drug Combinations; Esophagitis, Peptic; Glycyrrhetinic Acid; Humans; Randomized Controlled Trials as Topic; Recurrence; Silicates; Silicic Acid; Silicon Dioxide

Topics: Adolescent; Adult; Aged; Alginates; Aluminum Hydroxide; Bicarbonates; Carbenoxolone; Clinical Trials as Topic; Drug Combinations; Esophagitis, Peptic; Female; Glycyrrhetinic Acid; Humans; Middle Aged; Silicates; Silicic Acid; Silicon Dioxide

Topics: Alginates; Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Barrett Esophagus; Bethanechol Compounds; Bicarbonates; Carbenoxolone; Cimetidine; Constriction, Pathologic; Domperidone; Drug Combinations; Esophagitis, Peptic; Esophagogastric Junction; Furans; Histamine H2 Antagonists; Humans; Metoclopramide; Ranitidine; Silicates; Silicic Acid

Topics: Alginates; Aluminum Hydroxide; Antacids; Bicarbonates; Carbenoxolone; Cimetidine; Drug Combinations; Esophagitis, Peptic; Humans; Metoclopramide; Silicates; Silicic Acid; Sodium Bicarbonate

A retrospective analysis was carried out in 104 patients with peptic oesophagitis treated with Pyrogastrone (carbenoxolone with alginate-antacid) during a 3 1/2-year period. There wer 3 treatment groups: one had Pyrogastrone alone, another pyrogastrone with metoclopramide and in the third, both agents were given together with cimetidine. Highly significant symptomatic improvement was achieved in 85% of 96 patients treated between 4 and 8 weeks and equally significant endoscopic healing was noted in 76% of 55 patients for the same period. Best results were seen in those given Pyrogastrone alone; the concurrent use of metoclopramide and cimetidine did not enhance healing or symptom relief. 40% of patients received multiple courses, 22% were treated for at least six months and 16% for one year or longer continuously; 3 patients for over 3 years. The only noteworthy side effects were due to the tablet flavour and chewing property. These results confirm clinical trial experience that Pyrogastrone is highly effective in healing peptic esophagitis.

Topics: Adult; Aged; Alginates; Aluminum Hydroxide; Bicarbonates; Carbenoxolone; Cimetidine; Drug Combinations; Drug Therapy, Combination; Esophagitis, Peptic; Esophagoscopy; Female; Glycyrrhetinic Acid; Humans; Male; Metoclopramide; Middle Aged; Retrospective Studies; Silicates; Silicic Acid; Silicon Dioxide

Topics: Alginates; Aluminum Hydroxide; Antacids; Bicarbonates; Carbenoxolone; Drug Combinations; Esophagitis, Peptic; Glycyrrhetinic Acid; Humans; Silicates; Silicic Acid; Silicon Dioxide